Published in

MDPI, Microorganisms, 8(9), p. 1666, 2021

DOI: 10.3390/microorganisms9081666

Links

Tools

Export citation

Search in Google Scholar

Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients

Journal article published in 2021 by Veronica Di Cristanziano ORCID, Patrick Affeldt, Moritz Trappe, Maike Wirtz, Eva Heger, Elena Knops, Rolf Kaiser, Dirk Stippel ORCID, Roman-Ulrich Mueller, Roman-Ulrich Müller ORCID, Udo Holtick, Christoph Scheid, Martin Kann ORCID, Christine E. Kurschat ORCID, Franziska Grundmann ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

The treatment options for cytomegalovirus (CMV) infections in immunosuppressed patients are limited, mainly consisting of (val-)ganciclovir (VGC/GCV) as the first-line treatment. We report on three transplant recipients, one stem cell transplant (allo-HSCT) patient and two kidney transplant (KTx) recipients, with prolonged CMV viremia treated with a combined therapy based on letermovir (LMV), CMV-specific intravenous immunoglobulins (IVIg), and VGC/GCV, which led to the sustained control of CMV viremia in all patients.